{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:10:01Z","timestamp":1785481801214,"version":"3.56.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>As a form of precision medicine, this study aimed to investigate the specific patient population that would derive the greatest benefit from tildrakizumab, as well as the mechanism of action and efficacy of tildrakizumab in reducing the occurrence of psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To achieve this, a multi-center, prospective cohort study was conducted, involving a population of 246 psoriasis patients who had not received any systemic therapy or topical finger therapy between January 2020 and April 2023. Two independent clinicians, who were blinded to the study, analyzed nailfold capillary (NFC) abnormalities, such as nailfold bleeding (NFB) and enlarged capillaries, as well as the incidence of new PsA. Additionally, the factors that determined the response of psoriasis after seven months of tildrakizumab treatment were examined. The study also examined the quantity and role of regulatory T cells (Tregs) and T helper 17 cells both pre- and post-treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The severity of psoriasis, as measured by the Psoriasis Area and Severity Index (PASI), was found to be more pronounced in the tildrakizumab group (n=20) in comparison to the topical group (n=226). At 7 months after tildrakizumab treatment, multivariate analysis showed that those 65 years and older had a significantly better response to treatment in those achieved PASI clear or PASI 2 or less (Likelihood ratio (LR) 16.15, p&amp;lt;0.0001; LR 6. 16, p=0.01). Tildrakizumab improved the number and function of Tregs, which had been reduced by aging. Tildrakizumab demonstrated significant efficacy in improving various pathological factors associated with PsA. These factors include the reduction of NFB, enlargement of capillaries, and inhibition of PsA progression. The hazard ratio for progression to PsA was found to be 0.06 (95% confidence interval: 0.0007-0.46, p=0.007), indicating a substantial reduction in the risk of developing PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Tildrakizumab's effectiveness in improving skin lesions can be attributed to its ability to enhance the number and function of Tregs, which are known to decline with age. Furthermore, the drug's positive impact on NFB activity and capillary enlargement, both of which are recognized as risk factors for PsA, further contribute to its inhibitory effect on PsA progression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1286251","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:38:16Z","timestamp":1697701096000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["The optimal use of tildrakizumab in the elderly via improvement of Treg function and its preventive effect of psoriatic arthritis"],"prefix":"10.3389","volume":"14","author":[{"given":"Takemichi","family":"Fukasawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Norimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Yoshizaki-Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03159.x","article-title":"Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: Results of a German national survey","volume":"23","author":"Radtke","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.PUB5\/INFORMATION\/EN","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"2022","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.18128","article-title":"Mapping ethical and social aspects of biomarker research and its application in atopic dermatitis and psoriasis: a systematic review of reason","volume":"36","author":"Fritzsche","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1038\/S41598-022-18790-9","article-title":"Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)","volume":"12","author":"Graier","year":"2022","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet (London England)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-020-0677-5","article-title":"Why has Japan become the world\u2019s most long-lived country: insights from a food and nutrition perspective","volume":"75","author":"Tsugane","year":"2020","journal-title":"Eur J Clin Nutr 2020 756"},{"key":"B7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/BJD.19380","article-title":"Role of regulatory T cells in psoriasis pathogenesis and treatment","volume":"184","author":"Nussbaum","year":"2021","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3432","article-title":"Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis","volume":"20","author":"Komatsu","year":"2014","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.940705\/BIBTEX","article-title":"The dark side of Tregs during aging","volume":"13","author":"Palatella","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s002960050109","article-title":"Spondylitis is the most common pattern of psoriatic arthritis in Korea","volume":"19","author":"Baek","year":"2000","journal-title":"Rheumatol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAC664","article-title":"Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study","volume":"62","author":"Fukasawa","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1014","article-title":"Utility of nailfold capillary assessment for predicting pustulotic arthro-osteitis in palmoplantar pustulosis based on a prospective cohort study","author":"Fukasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/ANNRHEUMDIS-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ART.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13342","article-title":"Epidemiological analysis of psoriatic arthritis patients in Japan","volume":"43","author":"Yamamoto","year":"2016","journal-title":"J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13863","article-title":"Dermoscopic evaluation of melanonychia","volume":"44","author":"Koga","year":"2017","journal-title":"J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JAAD.2004.06.013","article-title":"Diagnosis and treatment of psoriatic arthritis","volume":"52","author":"Mease","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000238305","article-title":"Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients","volume":"219","author":"Quaglino","year":"2009","journal-title":"Dermatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3069521","article-title":"Notch1 signaling regulates the th17\/Treg immune imbalance in patients with psoriasis vulgaris","volume":"2018","author":"Ma","year":"2018","journal-title":"Mediators Inflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.5455\/MEDARH.2014.68.236-238","article-title":"Immunophenotype lymphocyte of peripheral blood in patients with psoriasis","volume":"68","author":"Karamehic","year":"2014","journal-title":"Med Arch (Sarajevo Bosnia Herzegovina)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0054895","article-title":"Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis","volume":"8","author":"Furuhashi","year":"2013","journal-title":"PLoS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLIM.2009.11.008","article-title":"Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity","volume":"135","author":"Zhang","year":"2010","journal-title":"Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.5021\/AD.2010.22.4.397","article-title":"Role of CD4CD25FOXP3 regulatory T cells in psoriasis","volume":"22","author":"Yun","year":"2010","journal-title":"Ann Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/S41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/JID.2011.200","article-title":"The dark side of regulatory T cells in psoriasis","volume":"131","author":"Soler","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7554\/ELIFE.67209","article-title":"Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model","volume":"10","author":"Fukasawa","year":"2021","journal-title":"Elife"},{"key":"B29","doi-asserted-by":"publisher","first-page":"kead287","DOI":"10.1016\/J.JAAD.2023.02.061","article-title":"Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial","volume":"13","author":"Fukasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAD287","article-title":"Impact of guselkumab on three cases of SSc accompanying psoriasis","author":"Fukasawa","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23158261","article-title":"Involvement of molecular mechanisms between T\/B cells and IL-23: from palmoplantar pustulosis to autoimmune diseases","volume":"23","author":"Fukasawa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/BJD.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1286251\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T07:38:32Z","timestamp":1697701112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1286251\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2023.1286251"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1286251","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"article-number":"1286251"}}